Table I.
Patient characteristics
| Number | Sex | Age (yrs) | EDSS | Duration (months) | Treatment | T2‐Vol (mm3) |
|---|---|---|---|---|---|---|
| 1 | f | 45 | 1.5 | 42 | GLT | 340 |
| 2 | f | 25 | 1.0 | 13 | INF‐ß‐1a | 320 |
| 3 | f | 28 | 0 | 46 | None | 493 |
| 4 | f | 43 | 1.5 | 6 | GLT | 541 |
| 5 | f | 35 | 1.5 | 22 | INF‐ß‐1b | 1250 |
| 6 | f | 29 | 2.0 | 10 | INF‐ß‐1b | 13600 |
| 7 | m | 35 | 0 | 9 | INF‐ß‐1a | 1123 |
| 8 | m | 29 | 1.5 | 1 | None | 959 |
| 9 | f | 34 | 1.5 | 3 | INF‐ß‐1a | 248 |
| 10 | f | 33 | 1.5 | 24 | GLT | 176 |
| 11 | m | 32 | 1.5 | 30 | Natalizumab | 792 |
| 12 | f | 39 | 1.0 | 2 | GLT | 827 |
| 13 | f | 24 | 1.5 | 18 | INF‐ß‐1b | 526 |
| 14 | f | 36 | 1.0 | 43 | None | 999 |
| 15 | m | 39 | 1.0 | 2 | None | 283 |
| 16 | f | 22 | 1.0 | 18 | INF‐ß‐1b | 572 |
Abbreviations: f = female; m = male; GLT = glatiramer acetate; INF‐ß = interferon‐ß; T2‐Vol = Volume of T2‐weighted lesions in the whole brain (note, that all patients were free of T2‐weighted lesions in the callosal motor fibers).